華盛頓港，紐約時間2016–04-26，生命科學(xué)的****者， Cadence和purification pall公司宣布，cadencetm分離器的商業(yè)化運營，聲波（CAS）分離工藝應(yīng)用在新的篇章，使用單一的文化bioprocess fluids clarification的細(xì)胞。CAS delivers*勁的收益，支持細(xì)胞和蛋白在封閉的系統(tǒng)中，當(dāng)用戶drastically centrifugation，減少成本和風(fēng)險。CAS是可用的和適當(dāng)?shù)牧⒓囱b運，并已在綜合英語教學(xué)pall很容易與其他的生命科學(xué)產(chǎn)品，使bioprocessing連續(xù)。

“我們在傳統(tǒng)單連續(xù)處理視覺的盡頭2015的概念的引入使聲波的波分離工藝作為一種工具，它的客戶包括橋之間的差距bioreactor和下游加工的火車。***的問題是，我們有一個概念的商業(yè)fruition發(fā)布的**時間在英語和英語，使launches系列產(chǎn)品連續(xù)bioprocessing”說，副總裁和總經(jīng)理的biopharmaceuticals egholm博士說，“時間eliminating信誠科技是真正的革命，他centrifugation文化clarification細(xì)胞減少，將緩沖區(qū)的要求在75 %，連續(xù)飼料流和文件，直接與我們的全集成的組合?！?br /> 生命科學(xué)的一個pall餾分分離工藝的**許可證是聲波的波（flodesign精音速隊在六月從2015 fds）。通過不同的CAS工程人員應(yīng)用聲波在流體的流量和countercurrent bioprocess波浪發(fā)電站，三dimensional公司在他們的nodes的陷阱。從這本leads aggregation和precipitation懸架，thereby”trapping”的簡單細(xì)胞的提取。CAS是酒店的clarifying biologic許多類型的產(chǎn)品，包括recombinant proteins協(xié)調(diào)和修改monoclonal抗體的變異，在文化particulate濃度和細(xì)胞密度，turbidity和viability。
CAS是一個動態(tài)的語言的節(jié)奏特點的產(chǎn)品組合，使公司運營的要點單元工藝為中心，在連續(xù)生產(chǎn)的monoclonal抗體和其他recombinant proteins。leverages的節(jié)奏組合的收益的單一特征的綜合利用工藝，它的結(jié)局結(jié)束，biomanufacturing控制解決方案，為客戶productivity和降低風(fēng)險。

英文原文：

PORT WASHINGTON, N.Y. – April 26, 2016 – Pall Life Sciences Biopharmaceutical division of global filtration, separation, and purification leader Pall Corporation, is pleased to announce the commercial launch of the CadenceTM Acoustic Separator (CAS), which applies acoustic wave separation technology in a novel single-use format for the clarification of cell culture bioprocess fluids. The CAS delivers robust, reliable cell and protein yields in a closed system without centrifugation, while drastically reducing user cost and risk. The CAS is available for immediate ordering and shipment, and has also been designed to be easily integrated with other Pall Life Sciences products to enable continuous bioprocessing.

“We launched our continuous processing vision at the end of 2015, introducing the concept of acoustic wave separation technology as an enabling tool for customers to bridge the critical gap between the bioreactor and the downstream processing train. We have now brought that concept to fruition with the commercial launch of the CAS as the first in a series of product launches that enable continuous bioprocessing,” said Vice President and General Manager of Biopharmaceuticals, Michael Egholm, Ph.D. “The CAS technology is truly revolutionary, eliminating reliance on centrifugation for cell culture clarification, reducing buffer requirements by around 75%, and creating a continuous feed stream for direct integration with our full portfolio.”

Pall Life Sciences obtained an exclusive license to acoustic wave separation technology in June 2015 from FloDesign Sonics (FDS). The CAS works via acoustic forces that are applied across a countercurrent flow of bioprocess fluid, generating three-dimensional standing waves that trap cells at their nodes. This leads to aggregation and precipitation from suspension, thereby “trapping” the cells for simple extraction. The CAS is capable of clarifying many types of biologic products, including recombinant therapeutic proteins and monoclonal antibodies, regardless of the variability in particulate concentrations and cell culture density, turbidity and viability.

The CAS is part of the Cadence product portfolio, which features enabling technologies for key unit operations required in the continuous production of monoclonal antibodies and other recombinant proteins. The Cadence portfolio leverages the benefits of single-use technologies to feature integrated, end to end biomanufacturing solutions that increase productivity and decrease risk for customers.